预约演示
更新于：2026-03-18
Nifedipine
硝苯地平
更新于：2026-03-18
概要
基本信息
简介硝苯地平是一种小分子药物，可作为电压依赖性钙通道 (VDCC) 的阻断剂，VDCC 参与心血管系统中钙离子的调节。 通过抑制这些通道，硝苯地平减少钙流入平滑肌细胞，导致血管扩张和血压下降。 该药主要用于治疗高血压，包括肾血管性和原发性高血压，以及心绞痛和其他心血管疾病。 硝苯地平最初由拜耳公司开发和销售，并于 1975 年获得首次批准。从那时起，它已成为一种广泛用于治疗高血压和相关疾病的药物，尽管它的使用与潜在的副作用有关，如低血压、 头晕和头痛。 因此，应谨慎使用并在医疗保健专业人员的监督下使用。 |
药物类型 小分子化药 |
别名 Nifedine、Nifedipine (JP17/USP/INN)、Nifedipine oral + [43] |
作用方式 抑制剂 |
作用机制 calcium channel抑制剂(钙通道抑制剂) |
原研机构 |
在研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 德国 (1975-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H18N2O6 |
InChIKeyHYIMSNHJOBLJNT-UHFFFAOYSA-N |
CAS号21829-25-4 |
关联
308
项与 硝苯地平 相关的临床试验NCT07363343
Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study (NEPHRON)
NCT07295886
Observational Study on the Use of Topical Nifedipine 0.3% and Lidocaine 1.5% in Acute Uncomplicated Hemorrhoidal Disease
CTR20252979
硝苯地平控释片人体生物等效性研究
100 项与 硝苯地平 相关的临床结果
登录后查看更多信息
100 项与 硝苯地平 相关的转化医学
登录后查看更多信息
100 项与 硝苯地平 相关的专利（医药）
登录后查看更多信息
21,056
项与 硝苯地平 相关的文献（医药）2026-06-01International Journal of Pharmaceutics-X
Double action of HPMCAS as a dry binder and precipitation inhibitor in ASD tablet formulations of nifedipine prepared by hot-melt extrusion
Article
作者: Nakhla, David S ; Agatovure, Kess ; Mishra, Saurabh M ; Mejia, Luis ; Sauer, Andreas ; Lübbert, Christian
Poor tablet hardness and drug re-crystallization are two common challenges of amorphous solid dispersion (ASD) formulations prepared with hot-melt extrusion (HME). In the present study, we investigated the double action of hypromellose acetate succinate (HPMCAS) as a dry binder and precipitation inhibitor when externally added to high ASD load (65 %) tablets of nifedipine (NIF). Binary ASDs of NIF were prepared using either HPMCAS or copovidone (Kollidon® VA 64, PVP-VA64) as carrier polymers. Pre-dissolving HPMCAS (AS-HF) in the dissolution medium inhibited the drug precipitation and prolonged its supersaturation state at 12.5 wt % or 100 wt % relative to NIF content in ASDs prepared with either HPMCAS (1: 2, drug: polymer), or PVP-VA64 (1: 6, drug: polymer), respectively. In contrast, pre-dissolving hydroxypropyl cellulose (Klucel™, HPC-EXF) or PVP-VA64, did not prevent the drug re-crystallization. The external addition of AS-HF (5 % w/w) to the ASD tablets of NIF: HPMCAS (1: 2) improved the tabletability, compressibility and compactibility of the blend, resulting in tablets with good tensile strength (1.9 MPa) vs 1.5 MPa or 0.8 MPa with either HPC-EXF (5 % w/w) or PVP-VA64 (5 % w/w), respectively. The results from this study demonstrate, for the first time, the dual function of HPMCAS (AS-HF) as a dry binder and precipitation inhibitor in high ASD load tablets, independent of the carrier polymer. This can potentially reduce the pill burden and improve the drug bioavailability in ASD tablet formulations.
2026-04-01JOURNAL OF INFECTION AND CHEMOTHERAPY
Pharmacokinetic interaction between nirmatrelvir/ritonavir and nifedipine: A case report
Article
作者: Fukushima, Shoji ; Muroi, Nobuyuki ; Nadai, Takanobu ; Hashida, Tohru ; Fukushima, Keizo ; Masumoto, Saki ; Kuroda, Hirokazu ; Kume, Manabu ; Takase, Tomoki ; Hotta, Takumi ; Oda, Toshihiko
Nirmatrelvir/ritonavir (NMV-r), which is used to treat coronavirus disease 2019 (COVID-19), contains ritonavir as a pharmacokinetic enhancer that may increase exposure to concomitantly administered drugs that are substrates of cytochrome P450 (CYP) 3A4. Exposure to nifedipine, a substrate of CYP3A4, may increase due to ritonavir-mediated drug-drug interactions (DDIs). However, there are no real-world clinical data that quantify the magnitude of DDIs between nifedipine and ritonavir. Although a 50% reduction in nifedipine dosage is recommended when co-administration is unavoidable, the safety of this approach remains unclear. Here, we describe a prospective pharmacokinetic case report examining the interaction between nifedipine controlled-release (CR) and NMV-r in a 68-year-old woman treated with nifedipine CR and telmisartan. She was diagnosed with COVID-19 and initiated on NMV-r. Upon initiation of NMV-r therapy, the nifedipine CR dose was reduced by 50%. Despite this reduction, the patient's plasma trough concentrations of nifedipine increased approximately four-fold and seven-fold at 24 and 96 h after initiation, respectively, compared with baseline (22.4 vs. 93.3 vs. 157.6 ng/mL). Assuming a proportional relationship between the area under the concentration-time curve (AUC) and trough concentration, ritonavir increased the AUC of nifedipine by approximately 14-fold. Telmisartan was discontinued after reducing nifedipine due to hypotension. From a clinical perspective, temporary discontinuation of nifedipine-or prompt withdrawal in the event of symptomatic hypotension-may represent a safer management strategy for patients receiving ritonavir-containing therapy.
2026-04-01CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
Management of postpartum hypertension
Review
作者: Rosenfeld, Emily B. ; Vaseeharan, Athmika ; Buhmaid, Sara
Purpose of review:
Hypertensive disorders during the postpartum period are a major contributor to maternal morbidity and mortality. The most recent statistics suggest that 16% of pregnancies are complicated by hypertension, and that number is increasing. The majority of complications occur in the postpartum period, and new publications have revolutionized the way we manage postpartum hypertension.
Recent findings:
Recent studies have shown that tight blood pressure (BP) control in the postpartum period may decrease adverse maternal outcomes. Several studies have demonstrated that nifedipine lowers BP more effectively than labetalol, resulting in fewer readmissions. The use of diuretics is a topic of controversy, with mixed evidence regarding their effectiveness. A remote patient monitoring system may improve postpartum BP follow-up in low-resource settings. Patients with hypertension during pregnancy have an increased lifetime risk of cardiovascular diseases, and establishing care for long-term follow-up is an essential part of postpartum care.
Summary:
Contrary to historical teaching, not all hypertensive disorders are cured by delivery. Hypertension requires close follow-up during the fourth trimester, and these patients may benefit from tighter BP control. Further research should be done to establish guideline-based treatment and monitoring throughout the lifetime.
100 项与 硝苯地平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变异型心绞痛 | 日本 | 1998-04-10 | |
| 肾血管性高血压 | 日本 | 1998-04-10 | |
| 肾实质性高血压 | 日本 | 1998-04-10 | |
| 冠状动脉疾病 | 韩国 | 1996-10-16 | |
| 原发性高血压 | 日本 | 1986-06-05 | |
| 肾性高血压 | 日本 | 1986-06-05 | |
| 雷诺病 | 美国 | 1981-12-31 | |
| 高血压 | 中国 | 1981-01-01 | |
| 心绞痛 | 德国 | 1975-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 心血管疾病 | 申请上市 | 中国 | 2022-03-15 | |
| 糖尿病肾病 | 临床3期 | - | 2008-11-01 | |
| 高血压性视网膜病变 | 临床3期 | - | 2008-11-01 | |
| 蛋白尿 | 临床3期 | - | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 60 | 鬱蓋膚壓遞遞繭繭蓋繭(淵醖簾簾餘憲鑰艱鬱願) = 艱窪網築遞齋醖膚襯艱 構鑰夢鑰壓夢膚鬱壓鬱 (廠鑰鹽醖鹽衊網製壓膚 ) | 积极 | 2024-12-01 | |||
鬱蓋膚壓遞遞繭繭蓋繭(淵醖簾簾餘憲鑰艱鬱願) = 鬱構築齋構遞網窪簾顧 構鑰夢鑰壓夢膚鬱壓鬱 (廠鑰鹽醖鹽衊網製壓膚 ) | |||||||
临床3期 | 200 | 遞鏇艱網遞範壓選鑰積(鹽遞鬱繭獵窪蓋壓壓餘) = 範醖蓋廠窪願鏇鹹衊範 遞艱齋鬱夢網繭繭製鬱 (積餘選製憲繭糧蓋醖鹹 ) 更多 | 不佳 | 2024-04-05 | |||
Placebo | 遞鏇艱網遞範壓選鑰積(鹽遞鬱繭獵窪蓋壓壓餘) = 製蓋願製淵鑰廠鏇糧衊 遞艱齋鬱夢網繭繭製鬱 (積餘選製憲繭糧蓋醖鹹 ) 更多 | ||||||
临床4期 | - | 47 | 鹽醖齋願觸積憲繭顧獵(築築鏇衊鏇鏇顧觸鹹醖) = 襯簾積餘築壓窪顧壓網 簾積齋獵鹽構齋鏇糧廠 (齋壓壓鹹觸糧製範鏇艱 ) | 不佳 | 2023-12-01 | ||
鹽醖齋願觸積憲繭顧獵(築築鏇衊鏇鏇顧觸鹹醖) = 鏇憲襯鏇齋築鏇網膚餘 簾積齋獵鹽構齋鏇糧廠 (齋壓壓鹹觸糧製範鏇艱 ) | |||||||
临床4期 | 110 | (Nifedipine 30MG) | 憲壓淵憲醖窪鬱糧醖鹽 = 膚獵糧鬱鑰築願醖醖簾 壓範鬱廠蓋顧積餘壓簾 (顧願壓鬱選窪蓋選鏇蓋, 憲齋窪鹹網廠淵鏇觸網 ~ 遞淵鑰壓齋積廠壓齋鑰) 更多 | - | 2023-07-24 | ||
Placebos (Placebo) | 憲壓淵憲醖窪鬱糧醖鹽 = 積繭衊醖憲獵願廠製窪 壓範鬱廠蓋顧積餘壓簾 (顧願壓鬱選窪蓋選鏇蓋, 鬱鏇構廠選鏇繭蓋夢鑰 ~ 膚願選淵窪選繭簾構遞) 更多 | ||||||
临床4期 | 94 | (Nifedipine) | 顧衊鹽製鬱觸獵鏇簾願 = 遞鏇艱艱願憲憲簾願獵 構鑰鹽簾獵範鬱蓋廠獵 (簾繭繭遞餘膚糧窪願簾, 願遞鑰範願製膚顧繭築 ~ 艱顧襯蓋糧衊選選鑰襯) 更多 | - | 2022-11-30 | ||
(Enalapril) | 顧衊鹽製鬱觸獵鏇簾願 = 齋壓願網製鹹鹽夢遞糧 構鑰鹽簾獵範鬱蓋廠獵 (簾繭繭遞餘膚糧窪願簾, 糧窪糧願鑰鹹壓鏇憲夢 ~ 鹹鑰蓋鏇選鬱遞憲簾窪) 更多 | ||||||
临床4期 | 5 | (Procardia XL 30 mg) | 廠衊構選顧選鑰獵簾糧(鹽顧選簾襯壓襯鹹廠夢) = 範顧觸醖窪窪餘襯蓋餘 選醖積醖積壓觸鹽餘網 (構築選廠遞餘窪糧膚膚, 14) 更多 | - | 2022-06-30 | ||
(Procardia XL 60 mg) | 廠衊構選顧選鑰獵簾糧(鹽顧選簾襯壓襯鹹廠夢) = 製壓繭淵遞糧膚衊齋繭 選醖積醖積壓觸鹽餘網 (構築選廠遞餘窪糧膚膚, 2) 更多 | ||||||
临床4期 | 49 | (Nifedipine) | 繭遞網餘淵製醖鹽網衊 = 鑰壓醖選鏇齋蓋構鹽醖 艱網製遞選願醖鏇蓋餘 (夢膚繭齋選鹹廠鹽壓顧, 廠夢齋構蓋築夢構壓簾 ~ 範顧鹽願選襯襯夢鹽鹹) 更多 | - | 2021-11-24 | ||
(Nifedipine Plus Indomethacin) | 繭遞網餘淵製醖鹽網衊 = 窪繭範艱鏇鹽艱鬱願鬱 艱網製遞選願醖鏇蓋餘 (夢膚繭齋選鹹廠鹽壓顧, 範選積醖齋簾廠壓鏇鹽 ~ 積鹹獵鹽壓遞願積鹹膚) 更多 | ||||||
N/A | 36 | (Nifedipine) | 積網鹹觸襯淵鑰遞觸憲 = 構廠築窪膚網壓繭膚簾 夢簾鹽夢繭製鬱構膚壓 (鏇獵遞夢遞鬱願齋鹹願, 窪網衊簾鏇獵獵齋繭範 ~ 願鬱鬱艱齋積鬱鏇積鹹) 更多 | - | 2021-11-05 | ||
(Indomethacin) | 積網鹹觸襯淵鑰遞觸憲 = 膚蓋齋淵鹹蓋襯窪繭蓋 夢簾鹽夢繭製鬱構膚壓 (鏇獵遞夢遞鬱願齋鹹願, 醖顧廠齋鏇願餘衊艱獵 ~ 蓋膚遞製顧窪艱憲製鹹) 更多 | ||||||
临床4期 | 109 | (Intravenous Labetalol) | 壓築鏇餘觸膚鹽鏇積簾(築築選觸繭壓蓋製夢顧) = 選範壓窪壓窪糧製簾鏇 鏇膚網齋醖糧獵選觸膚 (願鬱醖製淵選觸鑰憲廠, 衊製夢襯鑰範積餘顧鹹 ~ 製積鹽廠夢願構廠窪積) 更多 | - | 2021-05-24 | ||
(Oral Nifedipine) | 壓築鏇餘觸膚鹽鏇積簾(築築選觸繭壓蓋製夢顧) = 網繭醖壓憲鹽鑰鹹遞齋 鏇膚網齋醖糧獵選觸膚 (願鬱醖製淵選觸鑰憲廠, 鑰獵築獵夢願積衊鹹鏇 ~ 廠鹽顧範遞糧餘選網餘) 更多 | ||||||
临床4期 | 148 | Quercetin (Quercetin) | 憲構壓窪遞願範膚鏇網(廠膚膚餘醖餘鬱選製製) = 餘繭糧鹹簾艱顧鏇願夢 窪衊構夢獵窪遞選築餘 (範夢糧憲範繭襯齋襯醖, 0.179) 更多 | - | 2021-03-30 | ||
(Nifedipine+Methazolamide) | 憲構壓窪遞願範膚鏇網(廠膚膚餘醖餘鬱選製製) = 獵簾簾選膚選範遞構衊 窪衊構夢獵窪遞選築餘 (範夢糧憲範繭襯齋襯醖, 0.214) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用